H&Q Conference, January Effect, Etc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : H&Q Conference, January Effect, Etc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Giuseppe Scalamogna who wrote (134)	1/12/1997 6:30:00 PM
From: damniseedemons	of 246

Giuseppe, Being in phase II and III trials mean that these drugs are still far away. And the fact that they are powerful drugs, makes the FDA scrutinize them throughly (looking for side-effects). Recently, the FDA has been pushing drugs through the [limited] approval process in a swifter fashion. However, these drugs are usually for patients with essentially nothing to lose (they are probably going to die anyway, be it from being in the later stages of a fatal disease, or from harmful side-effects of the drugs they take). You should try to find approximate time estimates for the drugs in both NXCO's and GZTC's pipelines. The stocks will really start to move about 6 months ahead of time. Sal Habash

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next